Home > Cardiology > HFA 2021 > Late-Breaking Trials > Inconclusive results for dapagliflozin treatment in heart failure

Inconclusive results for dapagliflozin treatment in heart failure

Presented By
Prof. John McMurray, University of Glasgow, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
HFA 2021
Trial
DETERMINE-Reduced; DETERMINE-Preserved
Two trials on the efficacy of dapagliflozin in heart failure patients with preserved (HFpEF) and reduced (HFrEF) left ventricular function showed only partially significant results. Symptom improvement, for example, was found in HFrEF but not in HFpEF. “In patients with HFrEF, SGLT2 inhibitors have been shown to improve symptoms, to reduce HF hospitalisations, and even to improve survival, but we don’t know their effect on walking distance,” said Prof. John McMurray (University of Glasgow, UK) [1]. Prof. McMurray presented the results of the DETERMINE trials, which investigated the effect of dapagliflozin on symptoms and exercise capacity in HF patients. DETERMINE-Reduced (D-R; NCT03877237) enrolled 313 patients with HFrEF and DETERMINE-Preserved (D-P; NCT03877237) 5...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on